Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease
Open Access
- 14 February 2021
- journal article
- research article
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 24 (1) , 17-31
Abstract
BACKGROUND: Patients with Type 2 Diabetes (T2DM) and patients on maintenance hemodialysis (MHD) are at a high risk of adverse clinical course of COVID-19. To date, the causes of high mortality in these groups are not fully understood. Data about peculiarity of clinical course and Tocilizumab (TCZ) administration in patients with T2DM receiving MHD due to outcome of diabetic kidney disease (DKD) are not yet highlighted in current publications.AIMS: Identification of risk factors (RF) of adverse COVID-19 outcome and evaluation of TCZ administration in patients with T2DM receiving MHD due to DKD.MATERIALS AND METHODS: The patients treated in Moscow City Hospital No52 were included in retrospective observational study. The observation period was from 04.15 to 07.30 2020. The study endpoints were the outcomes of hospitalization — discharge or lethal outcome. Data were collected from electronic medical database. The following independent variables were analysed: gender, age, body mass index, time from the onset of symptoms to hospital admission, cardiovascular and general comorbidity (Charlson Index, CCI), cardiovascular event (CVE) during hospitalization, treatment in ICU, mechanical ventilation (MV), degree of lung damage according to CT data, level of prandial glycemia at admission, MHDassociated parameters (vintage, type of vascular access, frequency of complications). The autopsy reports were evaluated for the purpose of lethal structure investigation. In a subgroup treated TCZ the time from symptoms onset to TCZ administration and number of laboratory indicators were evaluated.RESULTS: 53 patients were included, mean age 68 ±9 y, males — 49%. General mortality in observation cohort was 45%, mortality in ICU — 81%, mortality on MV — 95%. High cardiovascular and general comorbidity was revealed (mean CCI — 8,3 ±1,5 points). The causes of outcomes according to autopsy reports data: CVE 37,5% (among them — acute myocardial infarction during hospitalization), severe respiratory failure — 62,5%. The independent predictors of lethal outcome were: MV (OR 106; 95% CI 11,5–984; р CONCLUSIONS: The number of RF of adverse COVID-19 outcome in patients with T2DM receiving MHD due to DKD are identified. CVE is one of the leading causes of mortality in study cohort. According to our experience the preventive (instead of rescue) strategy of TCZ administration should be used.Keywords
This publication has 54 references indexed in Scilit:
- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United StatesAmerican Journal of Kidney Diseases, 2019
- Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort StudyDiabetes Care, 2018
- Diabetic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2017
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsCirculation, 2014
- Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional interventionDiabetes, Metabolic Syndrome and Obesity, 2010
- Type 2 Diabetes and Pneumonia OutcomesDiabetes Care, 2007
- Etiology and Outcome of Community-Acquired Pneumonia in Patients With Diabetes MellitusChest, 2005
- Adapting the charlson comorbidity index for use in patients with ESRDAmerican Journal of Kidney Diseases, 2003
- Pulmonary Infectious Mortality Among Patients With End-Stage Renal DiseaseChest, 2001
- Diabetes and the Risk of Infection-Related Mortality in the U.S.Diabetes Care, 2001